Journal of Neuro-Oncology

, Volume 111, Issue 1, pp 1–10

EGFR mutation status in brain metastases of non-small cell lung carcinoma

  • Fanny Burel-Vandenbos
  • Damien Ambrosetti
  • Michael Coutts
  • Florence Pedeutour
Topic Review

DOI: 10.1007/s11060-012-0990-5

Cite this article as:
Burel-Vandenbos, F., Ambrosetti, D., Coutts, M. et al. J Neurooncol (2013) 111: 1. doi:10.1007/s11060-012-0990-5

Abstract

Brain metastases are a frequent and grave complication of non-small cell lung carcinoma (NSCLC). The prognosis is generally poor, despite standard therapy based on surgery and radiotherapy. A degree of understanding of the molecular basis of tumors has led to the development of targeted agents with promising initial findings for the treatment of NSCLC. EGFR mutations have been identified which are associated with significant sensitivity to EGFR tyrosine kinase inhibitors (TKI) and correlate with improved outcome in patients with NSCLC who are treated with these agents. The adoption of treatment tailored to the genetic make-up of individual tumors could lead to substantial therapeutic improvements, and such targeted therapy might be considered as a therapeutic option for brain metastases in the future. We review current knowledge about EGFR mutation status in the specific context of brain metastasis: its association with the response of brain metastases to TKI, its prevalence in brain metastases, and the correlation between mutation status in metastases as compared to the corresponding primary lung carcinoma.

Keywords

Brain metastasesEGFRLung cancerMutation status

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Fanny Burel-Vandenbos
    • 1
    • 2
    • 6
  • Damien Ambrosetti
    • 1
    • 3
  • Michael Coutts
    • 4
  • Florence Pedeutour
    • 5
  1. 1.Department of PathologyUniversity Hospital of NiceNiceFrance
  2. 2.INSERM U898/UNSA Stem Cells, Cancer and DevelopmentUniversity of Nice Sophia-AntipolisNiceFrance
  3. 3.Institute of Research on Cancer and Ageing in NiceUniversity of Nice Sophia-AntipolisNiceFrance
  4. 4.Department of PathologyWest Kent Oncology Centre, Maidstone HospitalKentUK
  5. 5.Genetics of Solid Tumours, Faculty of MedicineUniversity of Nice Sophia-AntipolisNiceFrance
  6. 6.Laboratoire Central d’Anatomie PathologiqueHopital PasteurNiceFrance